This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Blarcamesine
DrugBank Accession Number
DB05592
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 281.399
Monoisotopic: 281.177964365
Chemical Formula
C19H23NO
Synonyms
  • Anavex 2-73
  • Blarcamesine
  • Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanemethanamine
  • THD-DP-FM
External IDs
  • AE-37
  • AE37
  • ANAVEX 2-73 FREE BASE

Pharmacology

Indication

Investigated for use/treatment in breast cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9T210MMZ3F
CAS number
195615-83-9
InChI Key
BOTHKNZTGGXFEQ-UHFFFAOYSA-N
InChI
InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3
IUPAC Name
[(2,2-diphenyloxolan-3-yl)methyl]dimethylamine
SMILES
CN(C)CC1CCOC1(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
Not Available
ChemSpider
8057864

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentParkinsons Disease With Dementia (PDD)1
2, 3RecruitingTreatmentAlzheimer's Disease (AD)1
2, 3RecruitingTreatmentRett Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0197 mg/mLALOGPS
logP3.73ALOGPS
logP3.5Chemaxon
logS-4.2ALOGPS
pKa (Strongest Basic)9.54Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area12.47 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity87.57 m3·mol-1Chemaxon
Polarizability32.57 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 18, 2007 18:26 / Updated at February 21, 2021 18:51